Transform your preclinical study processes
Accelerate your research
Licensed at 36 sites in 12 countries, the submit™ platform is the leading solution for the creation and management of SEND datasets.
Shanghai-Based Drug Development Institute Purchases Expanded Package of Instem Solutions to Support Increasing Demand for Genetic Toxicology and ReproTox Services
Comments due by August 13th 2015
Organizations Around the Globe Continue to Become SEND-Enabled with Instem’s Submit Software Platform Following 2014 FDA Mandate
To help you evaulate systems, we believe that an initial, no-pressure demonstration carried out over the Internet is the way to go.
© 2015 Instem Group of Companies